Granulomatous hepatitis as a rare therapeutic complication

Czech version

Authors: K. Dvořák ¹; V. Šmíd ¹; R. Jakša ²
Authors‘ workplace: IV. interní klinika – klinika gastroenterologie a hepatologie 1. LF UK a VFN v Praze ¹; Ústav patologie, 1. LF UK a VFN v Praze ²
Published in: Gastroent Hepatol 2016; 70(2): 141-144
Category: Hepatology: Case Report
doi: https://doi.org/10.14735/amgh2016141

Overview

Intravesical BCG application is an established and relatively simple treatment for superficial carcinomas of the urinary bladder. It is usually well tolerated and has only mild side effects. We report a case of a 76-year-old immunocompetent man in whom this treatment led to a rare complication characterized by granulomatous hepatitis and pneumonitis. Elastography of the liver was used during diagnosis.

Key words:
granulomatous hepatitis – elastography – BCG – urinary bladder cancer

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
9. 3. 2016

Accepted:
7. 4. 2016

Sources

1. Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992; 19(3): 565–572.

2. Koga H, Kuroda M, Kudo S et al. Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. Int J Urol 2005; 12(2): 145–151.

3. Lamm DL, van der Meijden PM, Morales A et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992; 147(3): 596–600.

4. Rival G, Garot D, Mercier E et al. Acute respiratory failure and septic shock induced by Mycobacterium bovis. A rare side effect of intravesical BCG therapy. Presse Med 2006; 35(6 Pt 1): 980–982.

5. Liu J, Tran V, Leung AS et al. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin 2009; 5(2): 70–78.

6. Chang PE, Goh GB, Ngu JH et al. Clinical applications, limitations and future role of transient elastography in the management of liver disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 91–106. doi: 10.4292/wjgpt.v7.i1.91.

7. Wittes R, Klotz L, Kosecka U. Severe bacillus Calmette-Guerin cystitis responds to systemic steroids when antituberculous drugs and local steroids fail. J Urol 1999; 161(5): 1568–1569.

8. Elkabani M, Greene JN, Vincent AL et al. Disseminated Mycobacterium bovis after intravesicular bacillus Calmette-Guerin treatments for bladder cancer. Cancer Control 2000; 7(5): 476–481.

9. Delimpoura V, Samitas K, Vamvakaris I et al. Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy. BMJ Case Rep 2013; 2013: pii: bcr2013200624. doi: 10.1136/bcr-2013-200624.

10. Gonzalez OY, Musher DM, Brar I et al. Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003; 36(2): 140–148.